drugset / Trial / NCT06425341

A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B

NCT06425341

Phase 2 Recruiting 369 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

A multicenter, randomized, open, parallel-designed Phase II study to evaluate the efficacy and safety of HRS-5635 injection alone or in combination with other agents in patients treated for chronic hepatitis B.

Timeline

Start
2024-06-06
Primary completion
2026-08-30
Completion
2027-01-19

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-5635 Unknown Subcutaneous
Subject Peginterferon alfa-2a Protein / enzyme biologic Subcutaneous